List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9767296/publications.pdf Version: 2024-02-01

		66343	66911
121	6,534	42	78
papers	citations	h-index	g-index
122	122	122	5823
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	2021 Outstanding Early Career Scientists. Journal of Pharmaceutical Sciences, 2022, 111, 285.	3.3	0
2	2022 Scientific Advisors to the Editors (SAEs) Appointments. Journal of Pharmaceutical Sciences, 2022, , .	3.3	0
3	2022 Editorial Advisory Board (EAB) Appointments. Journal of Pharmaceutical Sciences, 2022, , .	3.3	0
4	The Jennifer Dressman Dedicated Issue. Journal of Pharmaceutical Sciences, 2022, 111, 1.	3.3	0
5	The RajÂSuryanarayanan (Sury) Dedicated Issue. Journal of Pharmaceutical Sciences, 2022, 111, 559.	3.3	0
6	Top reviewers for 2021. Journal of Pharmaceutical Sciences, 2021, , .	3.3	0
7	Editorial. Journal of Pharmaceutical Sciences, 2019, 108, 2823.	3.3	0
8	A Tribute to Ronald T. Borchardt—Teacher, Mentor, Scientist, Colleague, Leader, Friend, and Family Man. Journal of Pharmaceutical Sciences, 2016, 105, 370-385.	3.3	4
9	Placental ABC Transporters: Biological Impact and Pharmaceutical Significance. Pharmaceutical Research, 2016, 33, 2847-2878.	3.5	84
10	Editorial. Journal of Pharmaceutical Sciences, 2015, 104, 288-289.	3.3	0
11	The permeation of dynorphin A 1–6 across the blood brain barrier and its effect on bovine brain microvessel endothelial cell monolayer permeability. Peptides, 2012, 38, 414-417.	2.4	4
12	A Comprehensive Study Demonstrating that P-glycoprotein Function is Directly Affected by Changes in pH: Implications for Intestinal pH and Effects on Drug Absorption. Journal of Pharmaceutical Sciences, 2011, 100, 4258-4268.	3.3	8
13	Lipopolysaccharide Increases the Expression of Multidrug Resistance-Associated Protein 1 (MRP1) in RAW 264.7 Macrophages. Journal of NeuroImmune Pharmacology, 2010, 5, 516-520.	4.1	9
14	MRP isoforms and BCRP mediate sulfate conjugate efflux out of BeWo cells. International Journal of Pharmaceutics, 2010, 384, 15-23.	5.2	19
15	Expression and functional activities of selected sulfotransferase isoforms in BeWo cells and primary cytotrophoblast cells. Biochemical Pharmacology, 2009, 78, 1475-1482.	4.4	12
16	TCP-FA4: A derivative of tranylcypromine showing improved blood–brain permeability. Biochemical Pharmacology, 2009, 78, 1412-1417.	4.4	9
17	(3R,5S,7as)-(3,5-Bis(4-fluorophenyl)tetrahydro-1H-oxazolo[3,4-c]oxazol-7a-yl)methanol, a Novel Neuroprotective Agent㊥. Journal of Medicinal Chemistry, 2009, 52, 7537-7543.	6.4	8
18	Paclitaxel succinate analogs: Anionic and amide introduction as a strategy to impart blood–brain barrier permeability. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 5971-5974.	2.2	26

#	Article	IF	CITATIONS
19	Contributions of phosphorylation to regulation of OCTN2 uptake of carnitine are minimal in BeWo cells. Biochemical Pharmacology, 2008, 75, 745-751.	4.4	20
20	Investigation of the metabolism of substance P at the blood–brain barrier using LC–MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2007, 43, 1409-1415.	2.8	15
21	Sequence Recognition of <i>α</i> â€LFAâ€1â€derived Peptides by ICAMâ€1 Cell Receptors: Inhibitors of Tâ€cell Adhesion. Chemical Biology and Drug Design, 2007, 70, 237-246.	3.2	14
22	Low-affinity uptake of the fluorescent organic cation 4-(4-(dimethylamino)styryl)-N-methylpyridinium iodide (4-Di-1-ASP) in BeWo cells. Biochemical Pharmacology, 2007, 73, 891-900.	4.4	16
23	Synthesis and interactions of 7-deoxy-, 10-deacetoxy, and 10-deacetoxy-7-deoxypaclitaxel with NCI/ADR-RES cancer cells and bovine brain microvessel endothelial cells. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 433-436.	2.2	11
24	Characteristics of Substance P Transport Across the Blood–Brain Barrier. Pharmaceutical Research, 2006, 23, 1201-1208.	3.5	32
25	Single-site chemical modification at C10 of the baccatin III core of paclitaxel and Taxol C reduces P-glycoprotein interactions in bovine brain microvessel endothelial cells. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 495-498.	2.2	13
26	Tetrazole compounds: The effect of structure and pH on Caco-2 cell permeability. Journal of Pharmaceutical Sciences, 2006, 95, 717-725.	3.3	34
27	Role of P-glycoprotein in transplacental transfer of methadone. Biochemical Pharmacology, 2005, 69, 1869-1878.	4.4	84
28	Novel Organic Cation Transporter 2-Mediated Carnitine Uptake in Placental Choriocarcinoma (BeWo) Cells. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 192-198.	2.5	30
29	Chemical Modification of Paclitaxel (Taxol) Reduces P-Glycoprotein Interactions and Increases Permeation across the Bloodâ^'Brain Barrier in Vitro and in Situ. Journal of Medicinal Chemistry, 2005, 48, 832-838.	6.4	100
30	National Institute on Drug Abuse Conference report on placental proteins, drug transport, and fetal development. American Journal of Obstetrics and Gynecology, 2004, 191, 1858-1862.	1.3	13
31	Overcoming the Blood-Brain Barrier to Taxane Delivery for Neurodegenerative Diseases and Brain Tumors. Journal of Molecular Neuroscience, 2003, 20, 339-344.	2.3	44
32	The Presence of Inducible Cytochrome P450 Types 1A1 and 1A2 in the BeWo Cell Line. Placenta, 2003, 24, 45-52.	1.5	34
33	Efflux transporters of the human placenta. Advanced Drug Delivery Reviews, 2003, 55, 125-132.	13.7	148
34	Characteristics of the Fetal/Maternal Interface with Potential Usefulness in the Development of Future Immunological and Pharmacological Strategies. Journal of Pharmacology and Experimental Therapeutics, 2002, 301, 402-409.	2.5	34
35	Contribution of Efflux Pump Activity to the Delivery of Pulmonary Therapeutics. Current Drug Metabolism, 2002, 3, 1-12.	1.2	18
36	Investigation of substance P transport across the blood-brain barrier. Peptides, 2002, 23, 157-165.	2.4	37

#	Article	IF	CITATIONS
37	Effects of Poly(ethylene glycol) on Efflux Transporter Activity in Cacoâ€2 Cell Monolayers. Journal of Pharmaceutical Sciences, 2002, 91, 1980-1990.	3.3	136
38	A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit Pâ€glycoprotein activity in vitro. Journal of Pharmaceutical Sciences, 2002, 91, 1991-2002.	3.3	203
39	Amyloid peptide toxicity and microtubule-stabilizing drugs. Journal of Molecular Neuroscience, 2002, 19, 101-105.	2.3	22
40	Transport and metabolism of opioid peptides across BeWo cells, an in vitro model of the placental barrier. International Journal of Pharmaceutics, 2002, 233, 85-98.	5.2	29
41	Increasing paracellular porosity by E-cadherin peptides: discovery of bulge and groove regions in the EC1-domain of E-cadherin. Pharmaceutical Research, 2002, 19, 1170-1179.	3.5	51
42	Nitric Oxide and Blood–Brain Barrier Integrity. Antioxidants and Redox Signaling, 2001, 3, 273-278.	5.4	144
43	Conjugation with L-Glutamate forin vivoBrain Drug Delivery. Journal of Drug Targeting, 2001, 9, 23-37.	4.4	11
44	Modulation of P-glycoprotein activity in Calu-3 cells using steroids and β-ligands. International Journal of Pharmaceutics, 2001, 228, 171-179.	5.2	59
45	Progress and limitations in the use of in vitro cell cultures to serve as a permeability screen for the blood-brain barrier. Journal of Pharmaceutical Sciences, 2001, 90, 1681-1698.	3.3	247
46	P-glycoprotein efflux pump expression and activity in Calu-3 cells. Journal of Pharmaceutical Sciences, 2001, 90, 647-658.	3.3	82
47	Investigation of the metabolism of substance P at the blood-brain barrier using capillary electrophoresis with laser-induced fluorescence detection. Electrophoresis, 2001, 22, 3778-3784.	2.4	34
48	Improving the selectivity of HAV-peptides in modulating E-cadherin-E-cadherin interactions in the intercellular junction of MDCK cell monolayers. Pharmaceutical Research, 2001, 18, 446-453.	3.5	55
49	Carrier-mediated Transport of Folic Acid in BeWo Cell Monolayers as a Model of the Human Trophoblast. Placenta, 2001, 22, 863-869.	1.5	25
50	Characterization of the Calu-3 cell line as a tool to screen pulmonary drug delivery. International Journal of Pharmaceutics, 2000, 208, 1-11.	5.2	214
51	Carrier-mediated transport of valproic acid in BeWo cells, a human trophoblast cell line. International Journal of Pharmaceutics, 2000, 195, 115-124.	5.2	54
52	Functional expression of P-glycoprotein in primary cultures of human cytotrophoblasts and BeWo cellsâ~†. Reproductive Toxicology, 2000, 14, 217-224.	2.9	70
53	Fatty Acid Transport Regulatory Proteins in the Developing Rat Placenta and in Trophoblast Cell Culture Models. Placenta, 2000, 21, 367-375.	1.5	54
54	Enhancement of Transport of D-Melphalan Analogue by Conjugation with L-Glutamate across Bovine Brain Microvessel Endothelial Cell Monolayers. Journal of Drug Targeting, 2000, 8, 195-204.	4.4	24

#	Article	lF	CITATIONS
55	Carrier-mediated transport of monocarboxylic acids in BeWo cell monolayers as a model of the human trophoblast. Journal of Pharmaceutical Sciences, 1999, 88, 1288-1292.	3.3	24
56	Determination of angiotensin II in blood–brain barrier permeability studies using microbore LC with p-nitrophenyl-2,5-dihydroxyphenylacetate bis-tetrahydropyranyl ether as a pre-separation electrochemical labeling reagent. Analytica Chimica Acta, 1999, 394, 299-308.	5.4	6
57	Nutrient transport across the placenta. Advanced Drug Delivery Reviews, 1999, 38, 41-58.	13.7	120
58	Peptide transport and metabolism across the placenta. Advanced Drug Delivery Reviews, 1999, 38, 59-67.	13.7	25
59	Transport mechanisms for the antidepressant citalopram in brain microvessel endothelium. Brain Research, 1999, 831, 229-236.	2.2	71
60	Controlling drug delivery across the placenta. European Journal of Pharmaceutical Sciences, 1999, 8, 161-165.	4.0	109
61	AT1 Receptors Mediate Angiotensin II Uptake and Transport by Bovine Brain Microvessel Endothelial Cells in Primary Culture. Journal of Cardiovascular Pharmacology, 1999, 33, 30-35.	1.9	27
62	Partial maintenance of taurocholate uptake by adult rat hepatocytes cultured in a collagen sandwich configuration. Pharmaceutical Research, 1998, 15, 1533-1539.	3.5	76
63	Evaluation of the role of P-glycoprotein in ivermectin uptake by primary cultures of bovine brain microvessel endothelial cells. Neurochemical Research, 1998, 23, 203-209.	3.3	23
64	Comparison of the Effects of Potential Parenteral Vehicles for Poorly Water Soluble Anticancer Drugs (Organic Cosolvents and Cyclodextrin Solutions) on Cultured Endothelial Cells (HUV-EC). Journal of Pharmaceutical Sciences, 1998, 87, 1138-1143.	3.3	30
65	Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells. Peptides, 1998, 19, 1023-1030.	2.4	28
66	Gestational and smoking effects on peptidase activity in the placenta. Peptides, 1998, 19, 1659-1666.	2.4	11
67	Characterization of the A549 Cell Line as a Type II Pulmonary Epithelial Cell Model for Drug Metabolism. Experimental Cell Research, 1998, 243, 359-366.	2.6	531
68	Permeability and Metabolic Properties of a Trophoblast Cell Line (HRP-1) Derived from Normal Rat Placenta. Experimental Cell Research, 1997, 234, 147-155.	2.6	23
69	Modulation of cellular adhesion in bovine brain microvessel endothelial cells by a decapeptide. Brain Research, 1997, 747, 103-113.	2.2	50
70	Sucralfate effects on mucus synthesis and secretion by human gastric epithelium in vitro. International Journal of Pharmaceutics, 1996, 131, 159-169.	5.2	7
71	Evaluation of antiulcer agents with a human adenocarcinoma cell line (ACS). International Journal of Pharmaceutics, 1996, 129, 103-112.	5.2	6
72	Demonstration of sucralfate-mediated preservation of growth factor bioactivity in the presence of low pH with a human gastric epithelial cell line (AGS). Pharmaceutical Research, 1996, 13, 1122-1126.	3.5	4

#	Article	IF	CITATIONS
73	Passive Diffusion of Weak Organic Electrolytes across Cacoâ€2 Cell Monolayers: Uncoupling the Contributions of Hydrodynamic, Transcellular, and Paracellular Barriers. Journal of Pharmaceutical Sciences, 1995, 84, 1197-1204.	3.3	138
74	21-aminosteroid and 2-(aminomethyl)chromans inhibition of arachidonic acid-induced lipid peroxidation and permeability enhancement in bovine brain microvessel endothelial cell monolayers. Free Radical Biology and Medicine, 1995, 19, 349-357.	2.9	33
75	Biochemical characteristics of primary and passaged cultures of primate brain microvessel endothelial cells. Neurochemical Research, 1994, 19, 427-433.	3.3	19
76	Quantitative Approaches To Delineate Paracellular Diffusion in Cultured Epithelial Cell Monolayers. Journal of Pharmaceutical Sciences, 1994, 83, 1529-1536.	3.3	233
77	Cytotoxic effects of chlorhexidine and nystatin on cultured hamster buccal epithelial cells. International Journal of Pharmaceutics, 1994, 101, 121-126.	5.2	9
78	Uptake of surfactant-coated poly(methyl methacrylate)-nanoparticles by bovine brain microvessel endothelial cell monolayers. International Journal of Pharmaceutics, 1994, 110, 29-35.	5.2	98
79	Changes in brain microvessel endothelial cell monolayer permeability induced by adrenergic drugs. European Journal of Pharmacology, 1994, 269, 243-248.	2.6	69
80	Effect of some penetration enhancers on epithelial membrane lipid domains: evidence from fluorescence spectroscopy studies. Pharmaceutical Research, 1994, 11, 288-294.	3.5	41
81	Leucine enkephalin effects on brain microvessel endothelial cell monolayer permeability. Pharmaceutical Research, 1994, 11, 1366-1369.	3.5	3
82	Primary culture of rat gastric epithelial cells as an in vitro model to evaluate antiulcer agents. Pharmaceutical Research, 1994, 11, 77-82.	3.5	20
83	Leucine-enkephalin metabolism in brain microvessel endothelial cells. Peptides, 1994, 15, 109-116.	2.4	24
84	Leucine Enkephalin Effects on Paracellular and Transcellular Permeation Pathways Across Brain Microvessel Endothelial Cell Monolayers. Journal of Cardiovascular Pharmacology, 1994, 24, 818-825.	1.9	17
85	Sulfation of hypertensive and hypotensive drugs by monkey brain phenol sulfotransferase. Neurochemical Research, 1993, 18, 783-786.	3.3	3
86	Ammonium glycyrrhizinate (AMGZ) effects on membrane integrity. International Journal of Pharmaceutics, 1993, 94, 161-170.	5.2	4
87	Biotin uptake and transport across bovine brain microvessel endothelial cell monolayers. Pharmaceutical Research, 1993, 10, 282-288.	3.5	25
88	In vitro nasal transport across ovine mucosa: effects of ammonium glycyrrhizinate on electrical properties and permeability of growth hormone releasing peptide, mannitol, and lucifer yellow. Pharmaceutical Research, 1993, 10, 553-561.	3.5	41
89	Characterization of Dextromethorphan and Dextrorphan Uptake by a Putative Glutamic Acid Carrier and Passive Diffusion across Brain Microvessel Endothelium. Drug Delivery, 1993, 1, 113-118.	5.7	3
90	Tie-1 and tie-2 define another class of putative receptor tyrosine kinase genes expressed in early embryonic vascular system Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 9355-9358.	7.1	424

#	Article	IF	CITATIONS
91	Chlorhexidine Effects on Membrane Lipid Domains of Human Buccal Epithelial Cells. Journal of Dental Research, 1992, 71, 1298-1303.	5.2	28
92	Permeability of the blood-brain barrier to peptides: An approach to the development of therapeutically useful analogs. Peptides, 1992, 13, 1289-1294.	2.4	59
93	Effects of selected vasoactive substances on adenylate cyclase activity in brain, isolated brain microvessels, and primary cultures of brain microvessel endothelial cells. Neurochemical Research, 1992, 17, 209-214.	3.3	17
94	The effect of protein binding on ivermectin uptake by bovine brain microvessel endothelial cells. Veterinary Research Communications, 1992, 16, 365-377.	1.6	10
95	Blood—Brain Barrier: Transport Studies in Isolated Brain Capillaries and in Cultured Brain Endothelial Cells. Advances in Pharmacology, 1991, 22, 137-165.	2.0	54
96	Some characteristics of specific angiotensin II binding sites on bovine brain microvessel endothelial cell monolayers. Peptides, 1991, 12, 535-540.	2.4	16
97	Angiotensin Peptide Regulation of Bovine Brain Microvessel Endothelial Cell Monolayer Permeability. Journal of Cardiovascular Pharmacology, 1991, 18, 212-218.	1.9	38
98	Aminopeptidases of newborn bovine nasal turbinate epithelial cell cultures. International Journal of Pharmaceutics, 1991, 76, 247-255.	5.2	8
99	Evidence for 21-aminosteroid association with the hydrophobic domains of brain microvessel endothelial cells. Free Radical Biology and Medicine, 1991, 11, 361-371.	2.9	93
100	Angiotensin Peptide Regulation of Fluid-Phase Endocytosis in Brain Microvessel Endothelial Cell Monolayers. Journal of Cerebral Blood Flow and Metabolism, 1990, 10, 827-834.	4.3	48
101	The use of cultured epithelial and endothelial cells for drug transport and metabolism studies. Pharmaceutical Research, 1990, 07, 435-451.	3.5	246
102	Blood-brain barrier: Mechanisms of peptide regulation and transport. Journal of Controlled Release, 1990, 11, 51-59.	9.9	10
103	Fluid-phase endocytosis by primary cultures of bovine brain microvessel endothelial cell monolayers. Microvascular Research, 1990, 39, 1-14.	2.5	79
104	The application of bovine brain microvessel endothelial-cell monolayers grown onto polycarbonate membranes in vitro to estimate the potential permeability of solutes through the blood-brain barrier. Pharmaceutical Research, 1989, 06, 624-627.	3.5	66
105	Cultured buccal epithelium: an in vitro model derived from the hamster pouch for studying drug transport and metabolism. Pharmaceutical Research, 1989, 06, 160-166.	3.5	50
106	Substrate specificity of phenol sulfotransferase from primary cultures of bovine brain microvessel endothelium. Neurochemical Research, 1989, 14, 689-691.	3.3	20
107	Demonstration of Acid Hydrolase Activity in Primary Cultures of Bovine Brain Microvessel Endothelium. Journal of Cerebral Blood Flow and Metabolism, 1989, 9, 280-289.	4.3	20
108	Physicochemical factors affecting Î ² -adrenergic antagonist permeation across cultured hamster pouch buccal epithelium. International Journal of Pharmaceutics, 1989, 56, 135-142.	5.2	29

#	ARTICLE	IF	CITATIONS
109	Carrier-mediated transport of baclofen across monolayers of bovine brain endothelial cells in primary culture. Pharmaceutical Research, 1988, 05, 369-371.	3.5	76
110	Aluminum effects on brain microvessel endothelial cell monolayer permeability. International Journal of Pharmaceutics, 1988, 45, 249-257.	5.2	28
111	Bovine Brain Microvessel Endothelial Cell Monolayers as a Model System for the Blood-Brain Barrier. Annals of the New York Academy of Sciences, 1987, 507, 9-18.	3.8	168
112	Characteristics of Aminopeptidase Activity from Bovine Brain Microvessel Endothelium. Journal of Cerebral Blood Flow and Metabolism, 1987, 7, 801-805.	4.3	38
113	Relationship of octanol/buffer and octanol/water partition coefficients to transcellular diffusion across brain microvessel endothelial cell monolayers. International Journal of Pharmaceutics, 1986, 32, 79-84.	5.2	51
114	Characterization of an in vitro blood-brain barrier model system for studying drug transport and metabolism. Pharmaceutical Research, 1986, 03, 81-87.	3.5	224
115	Characteristics of the Large Neutral Amino Acid Transport System of Bovine Brain Microvessel Endothelial Cell Monolayers. Journal of Neurochemistry, 1986, 47, 484-488.	3.9	110
116	Catecholamineâ€Metabolizing Enzymes of Bovine Brain Microvessel Endothelial Cell Monolayers. Journal of Neurochemistry, 1986, 46, 1956-1960.	3.9	67
117	Tricyclic antidepressant drug effects on liposomal membranes. Biochemical Pharmacology, 1985, 34, 705-708.	4.4	5
118	Effect of Tricylic Antidepressant Drugs on Lymphocyte Membrane Structure. Immunopharmacology and Immunotoxicology, 1984, 6, 105-132.	0.8	14
119	Tricyclic Antidepressant Effects on the Murine Lymphocyte Mitogen Response. Immunopharmacology and Immunotoxicology, 1982, 4, 13-27.	0.8	27
120	Use of Fluorescent Probes to Monitor Propranolol Effects on the Murine Splenic Lymphocyte. Immunopharmacology and Immunotoxicology, 1982, 4, 329-353.	0.8	5
121	Characteristics of Tricyclic Antidepressant Binding Sites Associated with Murine Lymphocytes from Spleen. Immunopharmacology and Immunotoxicology, 1982, 4, 1-12.	0.8	18